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Abstract
Drug abuse represents a considerable burden of disease and has enormous economic impacts on 
societies. Over the years, few medications have been developed for clinical use. Their utilization is 
endowed with several limitations, including partial efficacy or significant side effects. On the other 
hand, the successful advancement of these compounds provides an important proof-of-concept for 
the feasibility of drug development programs in addiction. In recent years, a wealth of information 
has been generated on the psychological mechanisms, genetic or epigenetic predisposing factors, 
and neurobiological adaptations induced by drug consumption that interact with each other to 
contribute to disease progression. It is now clear that addiction develops through phases, from 
initial recreational use to excessive consumption and compulsive drug seeking, with a shift from 
positive to negative reinforcement driving motivated behaviors. A greater understanding of these 
mechanisms has opened new vistas in drug development programs. Researchers’ attention has 
been shifted from investigation of classical targets associated with reward to biological substrates 
responsible for negative reinforcement, impulse loss of control and maladaptive mechanisms 
resulting from protracted drug use. From this research, several new biological targets for the 
development of innovative therapies have started to emerge. The present article offers an overview 
of targets currently under scrutiny for the development of new medications for addiction. This 
work is not exhaustive but rather it provides a few examples of how this research has advanced in 
recent years by virtue of studies carried out in our laboratory.
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Introduction
Drug abuse and addiction represent a considerable burden of disease and cost for society 
(Uhl and Grow, 2004). Despite this, effective pharmacotreatments are still lacking, and the 
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few currently available medications suffer from significant limitations, including important 
side effects or restricted efficacy. For instance, drugs that are registered for the treatment of 
heroin addiction, such as methadone and buprenorphine, have reinforcing properties and 
thus can be themselves abused. Whereas the opioid antagonist naltrexone, which is used in 
the clinic for opioid and alcohol addiction appears to have limited efficacy restricted to a 
specific subpopulation of patients (Heilig et al., 2011). One of the factors that has hampered 
the development of effective medication in addiction is the extreme complexity of the 
biological mechanisms responsible for this psychiatric disease in which genetic 
vulnerability, environmental risk factors and their interaction play a determining role (also 
see the chapter of Quednow & Herdener “Human pharmacology for addiction medicine” in 
this volume).
Over the past decades, a wealth of information has been collected that has helped us unravel 
the neurobiological mechanisms responsible for maladaptive behaviors associated with the 
use of addictive drugs. The research in this field has advanced enormously, and the functions 
of several neurotransmitter systems, molecular pathways, and transcriptional and epigenetic 
mechanisms have started to be revealed (Robinson and Berridge, 1993; Shaham and Hope, 
2005; Le Moal and Koob, 2007; Thomas et al., 2008; Robison and Nestler, 2011). This new 
acquired knowledge has allowed for a more accurate dissection of the major facets of 
addiction, which includes drug reward and positive reinforcement, abstinence and negative 
reinforcement, craving, relapse to drug seeking, and impulsivity and compulsivity (Fig. 1).
With few exceptions, all addictive substances engage the mesolimbic dopamine reward 
pathway of the brain. It has been recognized that activation of this catecholaminergic circuit 
is critical for the rewarding and reinforcing properties of these drugs. The pleasurable effect 
experienced following exposure to a drug promotes the recreational use that often terminates 
into abuse and dependence (Gardner, 2000). However the role played by dopamine on 
human addiction is not fully disclosed yet. For example there are little evidences that opioids 
and cannabinoids induce reward and cause addiction through mesolimbic DA mechanisms. 
Additional or alternative processes may be involved in the acquisition of dependence for 
these substances (Nutt et al., 2015).
For a long time researchers in the drug of abuse field have mostly concentrated their 
attention on the study of positive reinforcement mechanisms (Koob et al., 2003); however, 
through the years, research has progressively highlighted other important but initially elusive 
aspects of substance abuse disorder.
For instance, it has been recognized that with protracted exposure to increasing daily doses 
of drugs, the reward or hedonic states associated with their consumption significantly 
decrease and the negative emotional states, such as anhedonia, dysphoria and anxiety, start 
to emerge. After this shift, substance use is no longer so pleasurable, and the drug is mostly 
taken to alleviate the aversive conditions (negative reinforcement) associated with its 
abstinence. At the beginning, drug use is episodic, but it rapidly progresses to a habitual 
consumption and, finally, to a compulsive, uncontrolled use characterized by chronic 
intoxication, followed by abstinence episodes that are usually accompanied by an intense 
and persistent urge for the drug and relapse (Fig. 1). Several factors may contribute to the 
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exacerbation of drug seeking and relapse; among the major ones are stress and 
environmental cues predictive of drug availability or previously associated with the 
pleasurable effect of the drug.
At the neuroanatomical level, the circuits that mediate the rewarding effects of drugs are 
partially different from those mediating drug-seeking and relapse. For instance, drug reward 
is largely controlled by the mesolimbic dopamine system that originates from the ventral 
tegmental area (VTA) and that sends afferents to the nucleus accumbens (Nac) (Koob et al., 
1998). On the contrary, drug-seeking and relapse are mediated by a complex network that 
includes the extended amygdala, hippocampus, dorsal striatum, prefrontal cortical structures 
and insula (Koob and Volkow, 2010). Moreover, several neurotransmitter systems and 
cellular mechanisms have been suggested to modulate the function of these circuitries; 
therefore, their potential involvement in shaping addictive responses has been proposed (Fig. 
2).
As a consequence of these advancements, new or previously unexplored drug targets have 
been proposed and are now under scrutiny for the development of innovative 
pharmacotherapeutic approaches beyond agents acting as drug reward modulators. In the 
present article, we reviewed some of the recent and most promising advancements in the 
identification and validation of these new targets. This work is not intended to be exhaustive 
but will focus on a few specific areas of development over the past decade that have shown 
major promise.
Peroxisome Proliferating Activator Receptors (PPARs)
PPARs are intracellular receptors that function as transcription factors (Issemann and Green, 
1990). Once activated by their ligand, PPARs translocate to the nucleus where they attach 
the retinoid receptor (RXR). The PPAR–RXR complex binds to PPAR response elements in 
DNA to modulate the transcription of different genes.
Three isotypes of PPARs have been identified (PPARα, PPARγ and PPARβ/δ). They are 
differentially distributed in body tissues but all are present in the brain (Woods et al., 2003; 
Moreno et al., 2004; Gofflot et al., 2007; Sarruf et al., 2009). PPARs are involved in insulin 
sensitization (Moller and Berger, 2003), fatty acid homeostasis (Aoyama et al., 1998), 
apoptosis (Roberts et al., 1998), inflammatory response and neuroprotection (Landreth and 
Heneka, 2001; Berger and Moller, 2002; Kapadia et al., 2008).
Endogenous ligands of PPARs are unsaturated fatty acids, such as palmitic, oleic, linoleic 
and arachidonic acid and leukotrienes. Unsaturated fatty acids are also ligands of PPARγ, 
and they also bind to prostaglandins and low density lipoprotein components (Varga et al., 
2011). Over the years, a number of synthetic ligands for PPARs have been developed, and 
some are marketed as drugs for the treatment of metabolic disorders (Schupp and Lazar, 
2010). PPARα ligands, such as gemfibrozil, bezafibrate, clofibrate and fenofibrate, are used 
for the treatments of dyslipidemia, whereas PPARγ agonists, such as pioglitazone and 
rosiglitazone, are used for the therapy of type 2 diabetes.
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Recent evidence supports the role of PPARα and PPARγ in addiction. For instance, PPARα 
and PPARγ are expressed in addiction-related brain areas, such as the lateral hypothalamus 
and the ventral tegmental area (VTA), from which dopamine (DA) release into the NAc can 
be modulated (Moreno et al., 2004; Sarruf et al., 2009; Melis et al., 2010; de Guglielmo et 
al., 2015b). In fact, electrophysiological experiments have shown that the activation of 
PPARα by fibrates decreased the ability of nicotine to enhance the firing rate of VTA DA 
neurons. This effect was accompanied with decreased levels of extracellular DA in the Nac 
(Melis et al., 2010; Panlilio et al., 2012). At the behavioral level, preclinical findings have 
shown that the PPARα agonist clofibrate blocked the acquisition of nicotine intake in rats 
and monkeys. Moreover, this drug reduced nicotine self-administration and prevented 
relapse to nicotine seeking precipitated by cues predictive of its availability or by nicotine 
priming (Panlilio et al., 2012). Similar results were observed with two other PPARα 
agonists, WY14643 and methyl oleoylethanolamide (Mascia et al., 2011). The behavioral 
and neurochemical effects of PPARα agonists were reversed following pretreatment with 
MK886, a selective PPARα antagonist. More recently, the efficacy of PPARα agonists in 
attenuating alcohol consumption and relapse to drug seeking in rodents have also been 
documented (Bilbao et al., 2015; Blednov et al., 2015).
Moreover, gene expression experiments have provided initial evidence of a link between 
PPARγ function and nicotine dependence (Amoruso et al., 2007); however, the most 
convincing data linking PPARγ to addiction came from pharmacological studies on alcohol 
and heroin. In these studies, it has been shown that the activation of PPARγ by chronic 
pioglitazone and rosiglitazone selectively decreased voluntary alcohol consumption in 
rodents (Stopponi et al., 2011). Moreover, pioglitazone markedly attenuated operant ethanol 
self-administration and reinstatement to alcohol seeking elicited by exposure to stress. 
Conversely, pioglitazone was not effective in controlling cue-induced relapse. Of note, when 
pioglitazone was administered in combination with naltrexone, a drug approved for the 
treatment of alcohol addiction in humans, a more robust inhibition of alcohol intake and a 
broader effect on relapse for alcohol resulted than when the two agents were given 
separately (Stopponi et al., 2013). These effects were selective for alcohol because it was 
shown in similar experiments that pioglitazone did not modify operant responding for 
saccharin. Interestingly, pioglitazone was also able to decrease the aversive symptoms 
associated with ethanol withdrawal that have an important clinical significance in alcohol 
relapse prevention (Stopponi et al., 2011).
Studies were also carried out to evaluate the effect of PPARγ agonists on opioid abuse. The 
results revealed that pioglitazone reduced heroin self-administration under both a fixed-ratio 
and progressive-ratio schedule of reinforcement. This effect was accompanied by a 
significant decrease of Nac extracellular DA levels following acute heroin infusion and a 
reduced VTA DA firing rate (de Guglielmo et al., 2015b). The activation of PPARγ was also 
shown to prevent the development of tolerance to the analgesic effects of morphine. 
Together, these findings suggest the possibility of combining PPARγ agonists with opioid 
agents to enhance the anti-addictive efficacy of antagonists (i.e., naltrexone) or to attenuate 
the abuse potential of agonists (i.e., buprenorphine or methadone). The possibility of 
combining PPARγ activators and opioid agonists for the development of analgesic therapies 
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endowed with low abuse liability is also envisioned. In this regard, it is worth mentioning 
that both pioglitazone and rosiglitazone have anti-inflammatory properties and appear to be 
effective in treating neuropathic pain in rodent models (Morgenweck et al., 2013).
CREB and the inhibition of phosphodiesterase (PDE) enzymes
Chronic drug use causes long-term structural and functional modifications in the brain. 
Underlying this process are alterations in the transcription of specific target genes. The 
modified expression will reshape the function of neuronal cells causing the remodeling of 
neurocircuitries formed by those neurons. The cAMP response element binding protein 
(CREB) is an important transcription factor that mediates the action of cAMP. A large body 
of evidence links CREB to the acquisition and the maintenance of dependence to drugs of 
abuse. Few excellent exhaustive reviews have been published that discuss the role of CREB 
in addiction (Carlezon et al., 2005; Robison and Nestler, 2011; Nestler, 2014). Hence, we 
will summarize only a few major findings generated over the past two decades.
One of the first findings was that mice with reduced CREB gene function showed decreased 
symptoms of morphine withdrawal (Maldonado et al., 1996). Consistently, the infusion of 
CREB antisense oligonucleotides in the locus coeruleus attenuated the appearance of 
morphine withdrawal symptoms (Lane-Ladd et al., 1997).
CREB is activated following chronic amphetamine administration in the rat striatum (Cole et 
al., 1995) and cocaine administration in the rat Nac (Carlezon et al., 1998), and it has been 
demonstrated that the rewarding effects of drugs of abuse are related to CREB activity 
within the Nac (Koob et al., 1998). The expression of a dominant-negative mutant CREB in 
this brain region enhanced the rewarding effects of cocaine and morphine, whereas CREB 
overexpression decreased the rewarding properties of both drugs (Carlezon et al., 1998; 
Barrot et al., 2002). Based on this latter evidence, the finding that overexpressing CREB in 
the Nac leads to a higher rate of cocaine self-administration should be interpreted as an 
attempt of the animal to load more drug to achieve reward (Larson et al., 2011). On the other 
hand, both exposure to chronic alcohol or nicotine decreased CREB activity within the Nac, 
which may reflect the classical hypohedonic state associated with protracted exposure to 
drugs of abuse (Misra et al., 2001; Pluzarev and Pandey, 2004).
To a large extent, evidence linking CREB function to drug abuse has been generated using 
mice with genetic modifications causing reduction in its expression or by manipulating the 
levels of this transcription factor in selected brain areas via viral mediated technologies 
(Carlezon et al., 1998; Barrot et al., 2002). These molecular approaches have provided 
advanced knowledge of the role of CREB in drug abuse; however, it is much harder to 
develop compounds that directly target this transcription factor as a clinical remedy for 
addiction.
An alternative possibility to modulate CREB is via protein kinase A (PKA)-mediated 
mechanisms. PKA is an enzyme located upstream of CREB that is responsible for its 
activation in dopamine receptor-containing neurons in mesolimbic circuitries (Greengard, 
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2001). A fine-tuning of PKA activity in these areas can be achieved by the regulation of 
phosphodiesterase (PDE) enzymes.
PDEs are enzymes that hydrolyze adenosine and guanosine cyclic nucleotides (cAMP and 
cGMP), the second messengers involved in a variety of physiological processes, which are 
responsible for PKA phosphorylation and whose activity has also been linked to addiction. 
For example, adaptive changes of the cAMP signaling within the mesocorticolimbic system 
occur following cocaine exposure and appear to play a role in the progression to dependence 
(Self et al., 1998; Lu et al., 2003).
Eleven members of the PDE family have been identified, and they differ in their specificity 
toward cAMP and cGMP, their kinetics, their intracellular localization, their expression in 
different brain nuclei, and their distinct roles in the regulation of CNS functions (Bender and 
Beavo, 2006).
Experience has demonstrated that PDEs represent suitable targets for pharmacological 
manipulation, and there are successful stories of PDE inhibitors being developed in the 
clinic. For instance, PDE5 selective blockers, such as sildenafil, vardenafil, and tadalafil, are 
used for erectile dysfunction and pulmonary hypertension (Montani et al., 2009; Chen et al., 
2015), whereas compounds that preferentially target PDE4, such as rolipram, have been 
developed for the treatment of asthma and chronic obstructive pulmonary disease (Spina, 
2004). In the CNS, the eleven PDE isoforms are all expressed (Bender and Beavo, 2006), but 
with respect to drugs of abuse, particularly attractive are PDE4, PDE7 and PDE10 because 
they are widely expressed in brain areas that are responsible for the regulation of motivated 
behavior, reward, learning and memory. Evidence linking the activity of these isoforms to 
drug abuse has started to emerge (Fujishige et al., 1999; Loughney et al., 1999; Soderling et 
al., 1999) (Miro et al., 2001; Reyes-Irisarri et al., 2005).
PDE4
PDE4 consists of four variants, PDE4 A, B, C, D, that are characterized by a “low Km” and 
cAMP-specific activity (Bender and Beavo, 2006). All four members are widely expressed 
in the brain with the highest levels in the basal ganglia, where the most expressed is PDE4B, 
the anterior cortex, the hippocampus and the hypothalamus, where all four variants have 
been found (Johansson et al., 2012).
Converging evidence reveals that the manipulation of PDE4 could result in a future of 
promising approaches for the treatment of opioid, alcohol and psychostimulant abuse. Initial 
findings showed that the inhibition of this PDE attenuated morphine tolerance and prevented 
the physical symptoms of morphine withdrawal in mice and rats (Itoh et al., 1998; Nunez et 
al., 2009). The PDE4 inhibitor, rolipram, has also been shown to be able to block relapse to 
heroin seeking induced by cues predictive of drug availability and by heroin priming in the 
rat (Lai et al., 2014). Rolipram also prevented the acquisition of morphine-induced 
Conditioned Place Preference (CPP) in mice (Thompson et al., 2004). This CPP result was 
later replicated in another study in which it was demonstrated that the VTA is an important 
brain site of action for the effect of rolipram on opioid reward.
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Substantial evidence also links PDE4 activity to cocaine. For instance, it was shown that 
rolipram was able to prevent the acquisition of cocaine-induced locomotor sensitization 
(Janes et al., 2009), whereas the activation of the cAMP cascade by both rolipram and Ro 
20-1724, another PDE4 inhibitor, was capable to block the acquistion of cocaine self-
administration (Knapp et al., 1999).
Finally, rolipram showed efficacy in reducing alcohol self-administration and intake in the 
rat (Wen et al., 2012). One potential limitation in the development of PDE4 inhibitors are 
side effects associated with their use in particular, vomiting and nausea, which are caused by 
inhibition of this enzyme in the nucleus of the solitary tract. These side effects appear to be 
predominantly associated with the inhibition of PDE4D (Lipworth, 2005). Hence, space for 
the development of selective PDE4 A, B, C inhibitors exists. New generations of brain 
penetrating PDE4 are under development, and their potential use for CNS disorders, 
including drug dependence, is envisioned.
PDE10A
In in vitro studies, PDE10A is responsible for the hydrolysis of both cAMP and cGMP; less 
is known in vivo. In the CNS, PDE10A shows the highest signal in the striatum, but 
substantial levels have also been identified in the hippocampus, thalamus and cerebellum 
(Fujishige et al., 1999; Loughney et al., 1999; Soderling et al., 1999). Due its large 
expression in striatal medium spiny neurons, a role for PDE10A in the modulation of basal 
ganglia function has been proposed (Wilson and Brandon, 2015). Several studies have 
demonstrated the preclinical efficacy of PDE10A inhibitors in models of Parkinson’s and 
psychosis (Chappie et al., 2009; Garcia et al., 2014). These findings have promoted 
aggressive drug development programs on this target, and few compounds are now under 
clinical development for the treatment of these disorders (Chappie et al., 2009; Garcia et al., 
2014). However, an alternative medical indication is addiction because their efficacy in 
animal models of drug abuse have recently been demonstrated.
For instance, it has been found that MP-10, a highly selective PDE10Ai blocked the 
acquisition of morphine CPP and facilitated extinction. Conversely, PDE10Ai did not 
prevent the expression of morphine CPP (Mu et al., 2014). A similar effect was observed 
with cocaine. Papaverine, which acts as a PDE10Ai, had no significant effect on the 
expression of cocaine-induced CPP (Liddie et al., 2012). Recently, it was also shown that 
MP-10 was able to reduce alcohol self-administration in rats with or without a history of 
exposure to stress. Moreover, MP-10 reduced alcohol operant responding in rats genetically 
selected for high alcohol preference and in alcohol-dependent rats. Brain microinjection 
experiments with MP-10 revealed that this effect was mediated by the dorsolateral striatum. 
Of note, the inhibition of PDE10A also decreased saccharin self-administration, suggesting a 
rather general involvement of this enzyme in the modulation of reward-related behaviors 
(Logrip et al., 2014). Consistent with this view, it was also shown that MP-10 impaired 
mouse performance when trained to achieve highly appetitive stimuli probably by affecting 
incentive salience attribution as suggested by authors (Piccart et al., 2013).
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Another PDE member of potential interest in addiction is PDE7. Like PDE4, PDE7 is highly 
selective for cAMP, especially at low levels of substrate. PDE7 consists of two variants, 
PDE7A and PDE7B, which are differentially distributed in the brain. PDE7A is highly 
represented in the substantia nigra, VTA, habenula and hippocampus, whereas the highest 
expression of PDE7B has been identified in the striatum, Nac and olfactory tubercles (Miro 
et al., 2001; Reyes-Irisarri et al., 2005). Importantly, approximately 70% of PDE7B-positive 
neurons in the dorsal striatum, Nac and olfactory tubercles are DA receptor-containing 
GABAergic neurons, which suggests an important role of this enzyme in the regulation of 
basal ganglion DA function (Reyes-Irisarri et al., 2005). Recently, the first evidence linking 
PDE7 to addiction was reported (Ciccocioppo et al., 2014b). In this work, it has been 
documented that the inhibition of PDE7 reduced nicotine self-administration under fixed- 
and progressive-ratio contingencies, whereas no effects on FR-1 food self-administration 
were observed. Enzyme inhibition also attenuated the cue- and stress-induced reinstatement 
of nicotine seeking. Based on the results of brain microinjection experiments, it was 
suggested that the effect of PDE7 inhibitors may be linked to their ability to modulate the 
mesolimbic DA system; thus, it is tempting to speculate that in addition to PDE4 and 
PDE10, PDE7 may also represent an interesting novel target for drug development in 
addiction.
Stress-related Neuropeptides
The modulation of appetitive behavior via direct or indirect manipulation of the mesolimbic 
DA system is the largest explored approach for the development of drug abuse treatments. 
The drug targets described above offer new possibilities to modulate positive reinforcement 
via the regulation of mesolimbic activity, which may be responsible, at least in part, for their 
promising efficacy in drug abuse. An alternative way to reduce the detrimental effects of 
drugs and to facilitate recovery from addiction is by acting on stress mechanisms and 
negative reinforcement.
In fact, protracted exposure to drugs leads to maladaptive alterations in physiological stress 
mechanisms and triggers negative reinforcement. These events represent two main 
landmarks of the transition from recreational drug use to abuse and dependence (Koob et al., 
1998; Schank et al., 2012). Once dependence is established, addicts tend to perseverate in 
the use of drugs to attenuate negative emotional states (i.e., anxiety, depression, anhedonia) 
and distress caused by drug abstinence (Koob, 2008). A large, and rather heterogeneous, 
family of neuropeptides has been shown to play a primary role as stress modulators, and a 
strong link with addiction has been documented for a few of them (Schank et al., 2012).
Corticotropin-Releasing Factor
A prototypical example of one of the neuropeptides involved in the modulation of the stress 
mechanism, negative reinforcement and addiction is the corticotropin-releasing factor 
(CRF), also known as corticotropin-releasing hormone. This stress-related neuropeptide 
drives both the peripheral and the central stress-response by binding to its cognate G-
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coupled receptors CRF1 and CRF2 (Bale and Vale, 2004). CRF initiates the neuroendocrine 
stress response by activating the hypothalamic-pituitary-adrenal (HPA) axis. In addition to 
this neuroendocrine role, CRF modulates the emotional aspects of the stress response by 
acting on receptors distributed in extrahypothalamic regions and that are responsible for 
mediating negative mood and distress (Primus et al., 1997; Sanchez et al., 1999; Van Pett et 
al., 2000).
As briefly mentioned above, addiction is characterized by three major domains, also 
conceptualized as a three-stage cycle in which the initial recreational use of drugs is 
followed by dependence and a withdrawal/negative effect, which is then followed by 
preoccupation/urge and, therefore, relapse to uncontrolled drug use (Koob and Volkow, 
2010). CRF is known to play a role in all three stages, but it is the primary actor in the 
regulation of the withdrawal/negative effect stage (Zorrilla et al., 2014), which is largely 
mediated by CRF1 receptors located in the extended amygdala, as has been demonstrated for 
alcohol (Hansson et al., 2007; Merlo Pich et al., 1995; Zorrilla et al., 2001; Olive et al., 
2002; Funk et al., 2006; Roberto et al., 2010), nicotine (George et al., 2007), cocaine 
(Richter and Weiss, 1999), opioids (Weiss et al., 2001) and cannabinoids (Rodriguez de 
Fonseca et al., 1997).
Preclinical studies have provided strong evidence supporting the potential usefulness of 
CRF1 receptor antagonists in treating addiction. CRF antagonists reduced elevated alcohol 
withdrawal-induced anxiety in dependent rats (Knapp et al., 2004; Breese et al., 2005; 
Gehlert et al., 2007; Sommer et al., 2008) and the anxiogenic-like response induced by 
cocaine, nicotine, cannabinoids, opiates, and benzodiazepines (Rodriguez de Fonseca et al., 
1997; Basso et al., 1999; Tucci et al., 2003; George et al., 2007; Skelton et al., 2007; Park et 
al., 2013). CRF1 antagonists were also able to decrease the self-administration of alcohol 
(Sabino et al., 2006; Chu et al., 2007; Funk et al., 2007; Gehlert et al., 2007; Gilpin et al., 
2008; Richardson et al., 2008), cocaine (Specio et al., 2008), nicotine (George et al., 2007), 
and heroin (Greenwell et al., 2009) in rats and mice. Most importantly, CRF1 antagonists 
have been shown to possess a marked ability to prevent relapse to drug seeking elicited by 
stress and to prolong drug abstinence in laboratory animals. Moreover, human genetic 
studies have suggested that CRF1R gene polymorphisms are associated with binge drinking 
and excessive drinking in humans (Treutlein et al., 2006). Together, these findings support 
the hypothesis that genetic variation at the CRF1R locus may represent an important element 
for the evolution of alcohol dependence, and according to the promising perspective 
highlighted by preclinical studies, there is hope that CRF1R antagonists may be efficacious 
in treating drug addiction. To date, none of the clinically tested CRF1R antagonists have 
passed to phase III for lack of efficacy, adverse side effects or because Phase II clinical trials 
are stil ongoing (Zorrilla et al., 2013; Kwako et al., 2015); however, a CRF1 antagonist, 
GSK561679, is now being tested in phase II (ClinicalTrials.gov Identifier: NCT01187511). 
It will be exciting to know the results of this ongoing investigation.
N/OFQ-NOP
A large body of evidence supports the possibility that Nociceptin/orphanin FQ receptor 
(NOP) agonists represent a promising approach to treat addiction, especially alcoholism.
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Nociceptin/orphanin FQ (N/OFQ), the endogenous ligand of NOP receptors, is a 17-amino 
acid neuropeptide that is structurally related to the opioid peptide dynorphin A (Meunier et 
al., 1995; Reinscheid et al., 1995; Nothacker et al., 1996). Despite its structural homology 
with opioid peptides, N/OFQ does not bind to mu, delta and kappa opioid receptors (MOP, 
DOP, KOP respectively), nor do opioid peptides activate the NOP receptor (Reinscheid et 
al., 1996). Functional studies have demonstrated that N/OFQ possesses anti-opioid and anti-
CRF properties because the activation of NOP attenuates the rewarding effects of morphine 
and prevents the anorectic, anxiogenic and stress-like effects of CRF (Ciccocioppo et al., 
2000; Ciccocioppo et al., 2001). Consistent with the anti-opioid nature of N/OFQ, it has 
been shown that the activation of NOP receptors blunts the reinforcing and motivational 
effects of alcohol across a range of behavioral measures, including alcohol intake 
(Ciccocioppo et al., 1999), CPP (Kuzmin et al., 2003) and relapse to alcohol seeking 
triggered by alcohol-associated cues (Ciccocioppo et al., 2004). In agreement with its anti-
CRF properties it has also been shown that N/OFQ administration prevents the foot-shock 
stress-induced reinstatement of alcohol seeking in the rat (Martin-Fardon et al., 2000). This 
property of N/OFQ to attenuate both forms of relapse is particularly noteworthy because it 
has been previously shown that blockade of the MOP opioid receptor by naltrexone blocks 
alcohol self-administration and cues but not stress-induced relapse (Le et al., 1999; Le et al., 
2000; Liu and Weiss, 2002), whereas CRF1 antagonism prevents relapse associated with 
stress but is unable to attenuate alcohol seeking elicited by conditioning factors (Le et al., 
1999; Le et al., 2000; Liu and Weiss, 2002).
Recent data have shown that the inhibition of drinking by a newly developed NOP agonist, 
namely MT1677, is highly pronounced following chronic administration, whereas drug 
effects appeared to be absent or very low following an acute injection. These data have been 
obtained in genetically selected alcohol-preferring Marchigian Sardiniam (msP) rats, an 
animal model of pathological drinking in which most of the published studies supporting a 
role of the NOP system in alcohol abuse have been carried out (Ciccocioppo et al., 1999; 
Ciccocioppo et al., 2004; Economidou et al., 2006; Economidou et al., 2011; Ciccocioppo et 
al., 2014a). In contrast with these findings, it was shown that NOP agonists did not attenuate 
drinking in heterogeneous Wistar rats, from which msP rats originate (Ciccocioppo et al., 
2006; Economidou et al., 2008). On the other hand, if heterogeneous Wistar rats are 
subjected to a history of alcohol intoxication, NOP agonists appear to gain efficacy (de 
Guglielmo et al., 2015a). Studies using in situ hybridization showed that compared to Wistar 
rats, msP have an upregulation of the N/OFQ system, with major differences occurring in the 
CeA, BNST, VTA and some cortical structures (Economidou et al., 2008).
Noteworthy, enhanced NOP and N/OFQ levels have been documented also in the CeA and 
BNST of heterogeneous Wistar rats following a history of alcohol intoxication (Aujla et al., 
2013). These findings prompt an intriguing hypothesis that in apparent contrast with the 
current view of a role of NOP agonists in addiction, suggests that enhanced NOP function 
may represent a vulnerable factor for the development of alcohol abuse and that the 
documented efficacy of NOP agonists may be related to their ability to desensitize the 
system. This hypothesis is supported by the following evidence: 1) NOP receptors are 
subjected to a very rapid desensitization following exposure to agonists (Spampinato et al., 
2007) and 2) NOP agonists are efficacious after protracted administration and under 
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circumstances in which the receptor system is hyperfunctioning (Ciccocioppo et al., 2014a). 
If this hypothesis is proven to be true, we should expect that not only NOP agonists but also 
NOP antagonists to reduce alcohol drinking. In addition, different from what is observed 
with agonists, the antagonists should also be efficacious following acute administration.
Recently, 11C-NOP-1A, a new radioligand for the nociceptin/orphanin FQ peptide (NOP) 
receptor with high affinity (Ki, 0.15 nM) and adequate lipophilicity (measured logD, 3.4) for 
PET brain imaging, has been developed (Pike et al., 2011). Using this ligand, it will be 
possible to obtain some information on whether genetic predisposition to alcoholism or 
protracted exposure to alcohol is associated with the upregulation of NOP receptor levels in 
rodents and humans. This study will help further clarify the potential of NOP as a treatment 
target for alcoholism and possibly other forms of addiction, opening new vistas for drug 
development programs on this peptidergic system.
Non-peptide, orally available and brain penetrant NOP receptor agonists and antagonists 
have been developed, and seem to have acceptable safety and tolerability. Some of these 
compounds are in relatively advanced stages of development, and a hypothesis concerning 
their efficacy in alcohol addiction can be tested in clinical trials (Witkin et al., 2014).
Compared to alcohol, less is known about the role of the N/OFQ system in the abuse of 
other drugs. A few studies have shown that N/OFQ blocked CCP elicited by morphine 
(Murphy et al., 1999; Ciccocioppo et al., 2000), whereas microdialysis data demonstrated 
that N/OFQ reduced morphine-induced dopamine release in the Nac (Di Giannuario and 
Pieretti, 2000). On the other hand, when N/OFQ was tested on operant heroin self-
administration, no effects of the peptide were reported (Walker et al., 1998). Of note, CPP is 
highly influenced by mesolimbic DA transmission DA whereas heroin-self-administration is 
largely independent from DA. This could explain why NOP agonists, even though able to 
blunt Nac DA levels and morphine CPP does not affect operant responsing for heroin 
(Gerrits and Van Ree, 1996; Sanchis-Segura and Spanagel, 2006; Tzschentke, 2007) NOP 
activation was shown to be effective also in preventing cocaine- and amphetamine-induced 
CPP (Kotlinska et al., 2002; Zhao et al., 2003); moreover, mice with constitutive deletion of 
NOP receptors were more sensitive to the effects of cocaine in a CPP paradigm (Marquez et 
al., 2008; Sakoori and Murphy, 2008).
Hypocretins/Orexins
Hypocretin-1/Orexin A and Hypocretin-2/Orexin B (Hcrt-1/OxA; Hcrt-2/OxB) are 
neuropeptides produced in the lateral, dorsomedial and perifornical hypothalamus (de Lecea 
et al., 1998; Sakurai et al., 1998) by neurons projecting throughout the brain (Peyron et al., 
1998). Both Hcrt-1/OxA and Hcrt-2/OxB bind to their cognate receptors orexin-1 (OX1) and 
orexin-2 (OX2), which are extensively expressed in the central nervous system due to the 
wide projections of Hcrt/Ox neurons (Trivedi et al., 1998). OX1 and OX2 seem to have 
differential roles with respect to drug addiction. OX1 has been implicated in the modulation 
of morphine, cocaine, nicotine, and alcohol seeking (Boutrel et al., 2005; Harris et al., 2005; 
Borgland et al., 2006; Lawrence et al., 2006; Pasumarthi et al., 2006; Harris et al., 2007; 
Dayas et al., 2008; Hollander et al., 2008; Richards et al., 2008; Cannella et al., 2009a; 
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Moorman and Aston-Jones, 2009; Kallupi et al., 2010; Plaza-Zabala et al., 2010; Jupp et al., 
2011; Plaza-Zabala et al., 2012; Ubaldi et al., 2015), whereas OX2 seems to have a less 
important role. Yet, it was recently documented that OX2 antagonism selectively reduced 
alcohol self-administration in respect to sucrose while showing no effect on cue-induced 
reinstatement (Brown et al., 2013).
The modulation of the drug-seeking response mediated by OX1 appeared to be mainly 
linked to the modulation of VTA-mediated mechanisms (Mahler et al., 2013). However, 
besides the VTA, other areas reach of Hcrt-1/OxA terminals, such as the prelimbic and 
orbitofrontal cortices, have been implicated in cue-induced alcohol seeking (Jupp et al., 
2011). An OX1 antagonist also blocked stress-induced reinstatement (Winsky-Sommerer et 
al., 2004; Boutrel et al., 2005; Richards et al., 2008), but this effect was independent of the 
VTA (Wang et al., 2009). A possible target for Hcrt-1/OxA in stress-induced reinstatement 
may be the extended amygdala, which is composed of the central amygdala (CeA) and the 
bed nucleus of the stria terminalis (BNST), where Hcrt-1/OxA neurons send afferent 
projections (Peyron et al., 1998; Schmitt et al., 2012). In addition, Hcrt-1/Ox-A may also 
modulate stress-induced reinstatement via the paraventricular hypothalamic nucleus (PVN) 
as it is highly innervated by orexin fibers. Indeed, the Hcrt-1/Ox-A-induced activation of 
approximately 96% and 45% of CRF-containing neurons in the PVN and the CeA, 
respectively (Sakamoto et al., 2004), which increases CRF and vasopressin expression in the 
PVN and activates the HPA axis (Al-Barazanji et al., 2001).
Several orexin receptor antagonists are under development; they can be divided into three 
classes: 1) dual orexin receptor antagonist (DORA); 2) OX1 selective receptor antagonist (1-
SORA) and 3) OX2 selective receptor antagonist (2-SORA). The most promising approach 
for addiction treatment is with 1-SORA because a wealth of preclinical data has shown that 
the inhibition of Ox1 attenuates the motivation for most drugs of abuse while being devoid 
of side effects, such as sleepiness and alteration of vigilance, two effects typically mediated 
by Ox2; however, nonselective antagonists may also have some space in addiction medicine. 
For example, they could have potential in cocaine abuse because the antagonism of Ox1 
appears to play a primary role in attenuating the motivation for this addictive agent, whereas 
blockade of Ox2 may lead to some sedative effects that in the case of psychostimulants 
abuse, are tolerable if not advantageous. Instead, it is less likely that DORA could be used 
for the treatment of addictive drugs, such as alcohol or opioids. In fact, in this case, blockade 
of Ox2 may enhance the risk of excessive inhibition of CNS function by potentiating the 
depressant properties of the addictive agents. Few orexin antagonists have been tested in the 
clinic, and recently, the US FDA approved suvorexant, the first dual antagonist registered for 
the treatment of primary insomnia (Boss and Roch, 2015). Another DORA, almorexant, was 
also tested in the clinic, but its use was stopped due to tolerability issues (Boss and Roch, 
2015). Selective Ox2 antagonists are also entering into clinical investigation for sleep 
disorders, and for some of them, phase I studies have already been successfully completed 
(Boss and Roch, 2015). On the other hand, less advanced is the development of selective 
Ox1 blockers; However, a number of molecules are rapidly making their way through 
preclinical stages, and soon, some of them could be available for their first clinical trials. 
Based on preclinical evidence, addiction is one of the major disease areas toward which 
these compounds could be oriented.
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The Neuropeptide S (NPS) is a 20 amino-acid peptide identified as the endogenous ligand 
for the deorphanized G-protein-coupled receptor 154 (GPCR 154), which is currently named 
the NPS receptor (NPSR). NPS is produced exclusively in three brainstem regions, the peri-
locus coeruleus (LC) area, the principal sensory trigeminal nucleus, and the lateral 
parabrachial nucleus. Conversely, the NPSR is widely distributed throughout the brain. The 
most peculiar feature of NPS is its paradoxical physio-pharmacological profile as it is a pro-
stress neuropeptide endowed with anxiolytic-like properties (Xu et al., 2004; Xu et al., 2007; 
Cannella et al., 2013).
The central administration of NPS reduced alcohol drinking and self-administration 
selectively in alcohol-preferring P rats with respect to non-preferring NP controls (Badia-
Elder et al., 2008; Cannella et al., 2009a; Cannella et al., 2009b). Additionally, an effect that 
was associated with the anxiolytic effects of NPS in excessive alcohol drinking in P rats is 
associated to alcohol's ability to relieve them from anxiety (Ciccocioppo et al., 2006; Badia-
Elder et al., 2008). Recently, it has been shown that the NPSR antagonist can decrease 
alcohol self-administration in non-preferring rats (Thorsell et al., 2013), which suggest that 
this system may have differential effects in alcohol-preferring subjects with respect to non-
preferring ones. NPSR antagonists have also been shown to blunt cocaine self-
administration (Schmoutz et al., 2012) and some consequences of alcohol and morphine 
intoxication and withdrawal (Ruggeri et al., 2010; Ghazal et al., 2013). For instance, NPSR 
mRNA was increased in post-dependent rats, in which the anxiolytic-like effects of NPS 
were more pronounced (Ruggeri et al., 2010; Ghazal et al., 2013). This finding may suggest 
that increased NPSR expression may be a neuroadaptation aimed to cope with withdrawal 
syndrome. Several studies have linked the pro-arousal and pro-stress effects of NPS with the 
reinstatement of drug seeking. It has been demonstrated that NPS, given ICV or into the 
lateral hypothalamus (LH), potentiated the reinstatement of ethanol seeking induced by 
environmental stimuli previously paired with ethanol and cocaine availability. The effect of 
NPS was specific and was not observed following re-exposure to cues predictive of non-
rewarding solutions (Cannella et al., 2009a; Kallupi et al., 2010). The permissive role of 
NPS on ethanol and cocaine seeking was mediated by the Hcrt-1/Ox-A system because 
peripheral administration of the OX1 receptor antagonist SB334867 completely blocked it 
(Cannella et al., 2009a; Kallupi et al., 2010). Further investigation demonstrated that NPS 
activates Hcrt-1/Ox-A neurons that project from the LH to the BNST and PVN, two areas 
classically involved in the modulation of the stress response; selective inhibition of Ox1 
receptors in these two areas completely abolished drug-seeking elicited by NPS (Ubaldi et 
al., 2015). Together, these findings suggest that the enhancement of the seeking response by 
NPS is mediated by pro-stress and pro-arousal mechanisms linked to the activation of the 
Ox1 system (Smith et al., 2006). NPSR antagonists represent a possible new way to develop 
relapse prevention treatment that may represent an alternative to Hcrt-1/Ox-A antagonists. 
Research linking the NPS system to addiction in humans is still at its infancy; however, 
interesting findings are starting to emerge. For instance, it is now known that in humans, 
NPSR is present in two isoforms deriving from a A>T single nucleotide polymorphism, 
resulting in an Asn107Ile exchange, which confers ten-fold higher potency to the 
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NPSR107Ile isoform (Reinscheid et al., 2005). This isoform of NPSR is associated with 
impulsivity, stress-sensitivity and alcohol use disorder (Laas et al., 2014; Laas et al., 2015), 
which is in line with preclinical data indicating that overfunction of the system may be 
linked to enhanced relapse propensity (Cannella et al., 2009a; Paneda et al., 2009; Kallupi et 
al., 2010).
NK1 Receptor
The neurokinin1 receptor (NK1R) is a member of the tachykinin receptor family that 
preferentially binds the tachykinin Substance P (Pennefather et al., 2004). It is well known 
that the activation of NK1 by Substance P (SP) regulates the stress response and induces 
anxiety-like behavior and that NK1R antagonists have anxiolytic-like properties (Santarelli 
et al., 2001; Ebner and Singewald, 2006; Ebner et al., 2008). The PVN receives substance P 
innervation, and NK1R stimulation activates the HPA axis, enhancing corticosterone release 
and the expression of CRF1R (Kawano and Masuko, 1992; Hamke et al., 2006; Mello et al., 
2007; Womack and Barrett-Jolley, 2007; Womack et al., 2007; Ebner et al., 2008). On the 
other hand, it was also reported that NK antagonist administration can increase 
adrenocorticotropic hormone (ACTH) release and CRF expression (Jessop et al., 2000) and 
that SP can suppress ACTH release (Jones et al., 1978)r. These effects of NK1R antagonists, 
however, occur in unstressed animals, and therefore, they suggest a tonic suppression of 
HPA axis activity by SP/NK1R. Thus, it is envisioned that under resting conditions, SP 
tonically inhibits HPA axis activity, but in stressful conditions, SP activates HPA. In humans, 
it seems more likely that the inhibitory effect of an NK1R antagonist on the HPA axis 
predominates as basal cortisol levels are not influenced but the stress-induced release of both 
ACTH and cortisol is blocked (George et al., 2008). Other than the stress response, NK1R 
also mediates catecholamine signaling in the mesolimbic, mesocortical, and nigrostriatal 
pathways. NK1R is expressed throughout the striatum, in dendrites of cholinergic 
interneurons (Pickel et al., 2000; Commons and Serock, 2009), whereas D1 medium spiny 
neurons in the Nac express SP and feed back to the substantia nigra (Le Moine and Bloch, 
1995; Whitty et al., 1995; Futami et al., 1998). The stimulation of NK1R in the substantia 
nigra or VTA induces dopaminergic firing (Barnes et al., 1990; West and Michael, 1991) and 
conditioned place preference (Boix et al., 1995; Nikolaus et al., 1999). The role of SP/NK1R 
in addiction has been tested on opioid, cocaine and alcohol. NK1R knockout mice did not 
develop CPP for morphine and displayed reduced psychomotor sensitization and morphine 
self-administration (Murtra et al., 2000; Ripley et al., 2002), Moreover, the selective 
inactivation of NK1R in the amygdala attenuated morphine consumption (Gadd et al., 2003). 
These findings suggest the potential of NK1R antagonism on opioid addiction, but initial 
human studies point to the opposite direction as the NK1R antagonist aprepitant potentiated 
the subjective and physiologic responses in opioid abusers (Walsh et al., 2013). NK1R have 
also been tested against psychostimulants, but the results are rather inconclusive. In fact, 
although they suppress cocaine-induced locomotion (Kraft et al., 2001), receptor blockade 
neither prevents cocaine self-administration nor attenuates cocaine-induced CPP (Murtra et 
al., 2000; Ripley et al., 2002; Gadd et al., 2003). Controversial effects have also been 
reported in the case of reinstatement experiments showing that NK1R agonism facilitated 
the reinstatement of cocaine seeking, but receptor antagonists did not block cocaine-priming 
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induced reinstatement (Placenza et al., 2004; Placenza et al., 2005). The data obtained with 
alcohol are more promising.
For instance, it was shown that NK1R knockout mice did not develop alcohol CPP, 
consumed less alcohol in a two-bottle choice paradigm and did not escalate alcohol 
consumption following repeated cycles of deprivation (George et al., 2008; Thorsell et al., 
2010). Moreover, NK1R antagonism reduced the stress-induced reinstatement of alcohol 
seeking (Schank et al., 2011). Yet, the operant alcohol self-administration and cue-induced 
reinstatement of alcohol seeking were not affected by treatments (Schank et al., 2011) 
(Steensland et al., 2010).
Initial human data are in line with preclinical findings as antagonists decreased alcohol 
craving in alcohol-dependent subjects in unprovoked conditions, under social stressors and 
upon exposure to alcohol-associated cues. In addition, an NK1R antagonist also decreased 
cortisol release induced by stress and cues (George et al., 2008).
Conclusion and Future Directions
Drug addiction is a serious disabling condition that has a dramatic impact on our societies 
and public health systems. The processes involved in the development of addiction are 
complex and involve interactions of several neurotransmitter systems, cell signaling and 
transcription mechanisms. Following chronic exposure to drugs of abuse, the brain is 
subjected to profound functional alterations to which genetic and environmental 
determinants also contribute. Despite the severity of the disorder and the dramatic impact it 
has on our lives, only few medications have been approved for addiction treatment. At 
present, only a minority of patients can benefit from the use of these medications, whereas 
the majority of addicts still remain poorly treated. To improve the impact of 
pharmacotherapy in addiction, it is critical to develop more efficacious and safer drugs. Over 
the past decade, a number of new mechanisms involved in the regulation of drug abuse and 
in the transition to addiction have been identified (Table 1), thus allowing the possibility to 
develop new pharmacological strategies. Here, we discussed a few of these potential new 
approaches that offer hope to obtaining useful medications in the near future. This review is 
not exhaustive as several other drug targets are under exploration; therefore, there is hope 
that many more therapeutic options will be available in the clinic in the near future.
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Schematic representation of the addiction cycle characterized by initial recreational drug 
use, followed by drug dose escalation, intoxication and episodic withdrawal and terminating 
in drug seeking and relapse. Drug targets for these different domains are depicted.
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Schematic representation of the hypothetical brain sites of action and neuronal substrates for 
new targets in addiction.
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Table 1
List of novel pharmacological targets explored for development of innovative treatments in addiction.









reinstatement reduce (Stopponi et al., 2011)




Nicotine PPARγ gene expression increase (Amoruso et al., 2007)
Pioglitazone Morphine tolerance reduce (de Guglielmo et al., 2015)
PPARα
Fenofibrate, Tesaglitazar,




Nicotine SA, cue-, priming-induced reinstatement reduce
(Panlilio et al., 2012)
(Mascia et al., 2011)
PDE4






(Itoh et al., 1998)
(Nunez et al., 2009)






(Thompson et al., 2004)
(Janes et al., 2009)
(Knapp et al., 1999)
PDE10A
MP-10 Alcohol SA reduce (Logrip et al., 2014)
MP-10 Morphine CPP reduce (Mu et al., 2014)
Papaverine Cocaine CPP reduce (Liddie et al., 2012)
CREB
KO mice, antisense
oligonucleotide Morphine Withdrawal reduce
(Maldonado et al., 1996)





(Carlezon et al., 1998)
(Barrot et al., 2002)
(Larson et al., 2011)














Alcohol withdrawal, SA reduce
(Knapp et al., 2004)
(Gehlert et al., 2007)
(Sommer et al., 2008)
(Sabino et al., 2006)
(Chu et al., 2007)
(Funk et al., 2007)
(Gilpin et al., 2008)




Cocaine Withdrawal, SA reduce (Basso et al., 1999)(Specio et al., 2008)
alpha-helical CRF(9-41)
MPZP Nicotine Withdrawal, SA reduce
(Tucci et al., 2003)










(Ciccocioppo et al., 1999)
(Kuzmin et al., 2003)
(Ciccocioppo et al., 2004)
(Martin-Fardon et al., 2000)
(Economidou et al., 2011)
N/OFQ Morphine CPP reduce (Ciccocioppo et al., 2000)
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(Murphy et al., 1999)
N/OFQ CocaineAmphetamine CPP reduce
(Kotlinska et al., 2002)
(Zhao et al., 2003)
OX1
SB-334867 Alcohol cue-, stress-induced
reinstatement reduce
(Lawrence et al., 2006)
(Richards et al., 2008)
SB-334867 Cocaine cue-, stress-induced
reinstatement reduce
(Smith et al., 2009)
(Boutrel et al., 2005)
SB-334867 Morphine cue-induced




(Cannella et al., 2009)









SA, CPP no effect
(Kallupi et al., 2010)
(Kallupi et al., 2013)






KO mice, L822429 Alcohol SA, CPP, stress-induced
reinstatement reduce
(George et al., 2008)
(Thorsell et al., 2010)
(Schank et al., 2011)
KO mice Morphine SA, CPP reduce (Murtra et al., 2000)(Ripley et al., 2002)
KO mice Cocaine SA, CPP, locomotor
sensitisation no effect (Ripley et al., 2002)
Abbreviations: Peroxisome proliferating activator receptors gamma (PPARγ), peroxisome proliferating activator receptors alpha 
(PPARα), cAMP response element-binding protein (CREB), phosphodiesterase 4 (PDE4), phosphodiesterase 10A (PDE10A), 
corticotropin-releasing factor receptor 1 (CRF1R), nociceptin opioid receptor (NOP), hypocretin-1/orexin A receptor (Ox1), neuropeptide 
S receptor (NPSR), neurokinin 1 receptor (NK1R), operant self-administration (SA), conditioned place preference (CPP).
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